Order Article Reprints

Chau I, Penel N, Soriano AO, Arkenau H-T, Cultrera J, Santana-Davila R, Calvo E, Le Tourneau C, Zender L, Bendell JC, et al. Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. Cancers. 2020; 12(10):2985. https://doi.org/10.3390/cancers12102985

Chau, Ian, Nicolas Penel, Andres O. Soriano, Hendrik-Tobias Arkenau, Jennifer Cultrera, Rafael Santana-Davila, Emiliano Calvo, Christophe Le Tourneau, Lars Zender, Johanna C. Bendell, and et al. 2020. "Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial" Cancers 12, no. 10: 2985. https://doi.org/10.3390/cancers12102985

Chau, I., Penel, N., Soriano, A. O., Arkenau, H.-T., Cultrera, J., Santana-Davila, R., Calvo, E., Le Tourneau, C., Zender, L., Bendell, J. C., Mi, G., Gao, L., McNeely, S. C., Oliveira, J. M., Ferry, D., Herbst, R. S., & Fuchs, C. S. (2020). Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. Cancers, 12(10), 2985. https://doi.org/10.3390/cancers12102985